Kazia Therapeutics (ASX:KZA)
released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
Out of 16 patients, one patient demonstrated a complete response and two patients experienced a partial response according to industry-standard RECIST criteria, making an overall response rate of 19 per cent.
The patient who experienced a complete response remains in remission some three years after her last dose of Cantrixil.
Shares in Kazia Therapeutics (ASX:KZA)
are trading 4.4 per cent higher at $1.42.